In recent years, prescription drug affordability boards (PDABs) have struggled as they implement their cost review and price-setting policies. Now, some states are attempting to cut out these regulatory processes entirely. Instead of creating new PDABs, some states...

The March meeting of the Maryland Prescription Drug Affordability Board (PDAB)  ignited significant concerns among a broad group of patient, physician, pharmacist and caregiver organizations. Recent legislation requires the PDAB to conduct an analysis on the impact of...

An oft-repeated talking point for proponents of prescription drug affordability boards is that capping the top-line price of medications will result in lower premiums and out-of-pocket spending by patients. But a new report from the Partnership to Fight Chronic...

A new cost-benefit analysis from Colorado’s Department of Regulatory Agencies reveals a concerning finding.

VCC examines the guidance being given to PDABs and why the suggestions are concerning. 

Prescription Drug Affordability Boards (PDABs) claim to save patients money, but state records show a years-long trail of millions spent with no savings produced. The first PDAB was created in 2019 under the guise of lowering health care costs for people in Maryland,...

State-based Prescription Drug Affordability Board’s (PDABs) have an important goal – to cut health care costs by reducing spending on prescription drugs.  However, in an effort to do so, PDAB actions often overlook the complexities of America’s health care system and...

A recent survey of independent pharmacists should serve as a warning about the unintended consequences of upper payment limits. 

Colorado and Maryland Prescription Drug Affordability Boards are both in the process of considering how to set upper payment limits.

Two states now seem to be in a race to implement processes for setting upper payment limits.